Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152318 · ClinicalTrials.gov registry record · Phase 1
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
A Phase 1 study of Brain Tumor and Ependymoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 5
- Study locations
NCT03152318 is a Phase 1 study of Brain Tumor and Ependymoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 62 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (78% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03152318, a Phase 1 study of Brain Tumor and Ependymoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG rQNestin
- PROCEDURE Stereotactic biopsy
Study Locations (5)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Brigham and Women's Hospital - Boston
Maryland
- Johns Hopkins University Medical Center - Baltimore
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2017-07-18 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152318
The ClinicalTrials.gov registry entry for NCT03152318 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (78% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Brain Tumor appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03152318 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT03152318 about?
NCT03152318 is a clinical study titled "A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2". This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment f...
What is the current status of trial NCT03152318?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2017-07-18. Estimated completion is 2028-01.
What conditions does trial NCT03152318 study?
This clinical trial studies the following conditions: Brain Tumor, Ependymoma, Astrocytoma, Oligodendroglioma, Malignant Glioma of Brain.
What interventions are being tested in trial NCT03152318?
The interventions under investigation include: Cyclophosphamide (DRUG), rQNestin (DRUG), Stereotactic biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03152318?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03152318 being conducted?
This trial has 5 study locations across Maryland, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.